IBDEI0XS ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16679,0)
 ;;=203.00^^92^940^103
 ;;^UTILITY(U,$J,358.3,16679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16679,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,16679,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,16679,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,16680,0)
 ;;=203.01^^92^940^105
 ;;^UTILITY(U,$J,358.3,16680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16680,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,16680,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,16680,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,16681,0)
 ;;=238.6^^92^940^108
 ;;^UTILITY(U,$J,358.3,16681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16681,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,16681,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,16681,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,16682,0)
 ;;=205.00^^92^940^4
 ;;^UTILITY(U,$J,358.3,16682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16682,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,16682,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,16682,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,16683,0)
 ;;=205.01^^92^940^6
 ;;^UTILITY(U,$J,358.3,16683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16683,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,16683,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,16683,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,16684,0)
 ;;=205.10^^92^940^19
 ;;^UTILITY(U,$J,358.3,16684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16684,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,16684,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,16684,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,16685,0)
 ;;=205.11^^92^940^21
 ;;^UTILITY(U,$J,358.3,16685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16685,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,16685,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,16685,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,16686,0)
 ;;=289.0^^92^940^55
 ;;^UTILITY(U,$J,358.3,16686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16686,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,16686,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,16686,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,16687,0)
 ;;=238.4^^92^940^109
 ;;^UTILITY(U,$J,358.3,16687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16687,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,16687,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,16687,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,16688,0)
 ;;=V58.61^^92^940^126
 ;;^UTILITY(U,$J,358.3,16688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16688,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,16688,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,16688,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,16689,0)
 ;;=282.49^^92^940^117
 ;;^UTILITY(U,$J,358.3,16689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16689,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,16689,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,16689,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,16690,0)
 ;;=289.89^^92^940^15
 ;;^UTILITY(U,$J,358.3,16690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16690,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,16690,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,16690,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,16691,0)
 ;;=238.79^^92^940^88
 ;;^UTILITY(U,$J,358.3,16691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16691,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,16691,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,16691,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,16692,0)
 ;;=287.30^^92^940^110
 ;;^UTILITY(U,$J,358.3,16692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16692,1,4,0)
 ;;=4^287.30
